Halozyme Therapeutics reports 4.67% revenue growth and 40.3% net margin, with analysts' price targets ranging from $52 to $65.
Halozyme Therapeutics (NASDAQ: HALO), focused on oncology therapies, has a market cap below industry standards and reported a 4.67% revenue growth as of June 30, 2024. Despite this, it boasts a strong net margin of 40.3%. Analysts' views vary, leading to an average 12-month price target of $62.50, up from $60.92. Key analysts maintain or adjust their ratings, with several recommending a "Buy" at prices ranging from $52 to $65.
October 25, 2024
5 Articles